Keywords
Last Name
Institution

Christopher F. Basler

TitlePROFESSOR
InstitutionMount Sinai
DepartmentMicrobiology
Address

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Binning JM, Wang T, Luthra P, Shabman RS, Borek DM, Liu G, Xu W, Leung DW, Basler CF, Amarasinghe GK. Development of RNA Aptamers Targeting Ebola Virus VP35. Biochemistry. 2013 Nov 26; 52(47):8406-19.
      View in: PubMed
    2. Li Z, Xu J, Chen Z, Gao X, Wang LF, Basler C, Sakamoto K, He B. The L gene of j paramyxovirus plays a critical role in viral pathogenesis. J Virol. 2013 Dec; 87(23):12990-8.
      View in: PubMed
    3. Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med. 2013 Aug 14; 5(198):198ra107.
      View in: PubMed
    4. Luthra P, Ramanan P, Mire CE, Weisend C, Tsuda Y, Yen B, Liu G, Leung DW, Geisbert TW, Ebihara H, Amarasinghe GK, Basler CF. Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe. 2013 Jul 17; 14(1):74-84.
      View in: PubMed
    5. Basler CF. A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein. Expert Rev Anti Infect Ther. 2013 May; 11(5):475-8.
      View in: PubMed
    6. Shabman RS, Hoenen T, Groseth A, Jabado O, Binning JM, Amarasinghe GK, Feldmann H, Basler CF. An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog. 2013 Jan; 9(1):e1003147.
      View in: PubMed
    7. Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF. Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol. 2013 Apr; 87(7):3801-14.
      View in: PubMed
    8. Martinez O, Ndungo E, Tantral L, Miller EH, Leung LW, Chandran K, Basler CF. A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner. J Virol. 2013 Mar; 87(6):3324-34.
      View in: PubMed
    9. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE, Wilson IA, Basler CF. Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog. 2012; 8(12):e1003067.
      View in: PubMed
    10. Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, Otwinowski Z, Liu G, Huh J, Basler CF, Amarasinghe GK. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A. 2012 Dec 11; 109(50):20661-6.
      View in: PubMed
    11. Weisfuse IB, Tsibane T, Konty KJ, Egger JR, Waddell EN, Rahmat S, Harris E, Olson DR, Basler CF. Seroprevalence of pandemic influenza viruses, New York, New York, USA, 2004. Emerg Infect Dis. 2012 Nov; 18(11):1905-7.
      View in: PubMed
    12. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis. 2013 Jan 1; 207(1):98-105.
      View in: PubMed
    13. Hoenen T, Shabman RS, Groseth A, Herwig A, Weber M, Schudt G, Dolnik O, Basler CF, Becker S, Feldmann H. Inclusion bodies are a site of ebolavirus replication. J Virol. 2012 Nov; 86(21):11779-88.
      View in: PubMed
    14. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Albrecht R, Blum DL, Ramos I, Fernandez-Sesma A, Edwards KM, García-Sastre A, Basler CF, Crowe JE. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol. 2012 Jun; 86(11):6334-40.
      View in: PubMed
    15. Martinez O, Leung LW, Basler CF. The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res. 2012 Mar; 93(3):416-28.
      View in: PubMed
    16. Leung DW, Basler CF, Amarasinghe GK. Molecular mechanisms of viral inhibitors of RIG-I-like receptors. Trends Microbiol. 2012 Mar; 20(3):139-46.
      View in: PubMed
    17. Basler CF. Nipah and hendra virus interactions with the innate immune system. Curr Top Microbiol Immunol. 2012; 359:123-52.
      View in: PubMed
    18. Reynard O, Reid SP, Page A, Mateo M, Alazard-Dany N, Raoul H, Basler CF, Volchkov VE. Unconventional secretion of Ebola virus matrix protein VP40. J Infect Dis. 2011 Nov; 204 Suppl 3:S833-9.
      View in: PubMed
    19. Leung LW, Martinez O, Reynard O, Volchkov VE, Basler CF. Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry. J Infect Dis. 2011 Nov; 204 Suppl 3:S973-7.
      View in: PubMed
    20. Martinez O, Tantral L, Mulherkar N, Chandran K, Basler CF. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis. 2011 Nov; 204 Suppl 3:S825-32.
      View in: PubMed
    21. Shabman RS, Gulcicek EE, Stone KL, Basler CF. The Ebola virus VP24 protein prevents hnRNP C1/C2 binding to karyopherin a1 and partially alters its nuclear import. J Infect Dis. 2011 Nov; 204 Suppl 3:S904-10.
      View in: PubMed
    22. Shabman RS, Leung DW, Johnson J, Glennon N, Gulcicek EE, Stone KL, Leung L, Hensley L, Amarasinghe GK, Basler CF. DRBP76 associates with Ebola virus VP35 and suppresses viral polymerase function. J Infect Dis. 2011 Nov; 204 Suppl 3:S911-8.
      View in: PubMed
    23. Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. Filoviral immune evasion mechanisms. Viruses. 2011 Sep; 3(9):1634-49.
      View in: PubMed
    24. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol. 2011 Oct 1; 187(7):3704-11.
      View in: PubMed
    25. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol. 2011 Oct; 85(20):10905-8.
      View in: PubMed
    26. Vilchèze C, Baughn AD, Tufariello J, Leung LW, Kuo M, Basler CF, Alland D, Sacchettini JC, Freundlich JS, Jacobs WR. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother. 2011 Aug; 55(8):3889-98.
      View in: PubMed
    27. Walpita P, Barr J, Sherman M, Basler CF, Wang L. Vaccine potential of Nipah virus-like particles. PLoS One. 2011; 6(4):e18437.
      View in: PubMed
    28. Valmas C, Basler CF. Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J Virol. 2011 May; 85(9):4309-17.
      View in: PubMed
    29. Leung LW, Park MS, Martinez O, Valmas C, López CB, Basler CF. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol. 2011 Oct; 89(7):792-802.
      View in: PubMed
    30. Leung DW, Prins KC, Basler CF, Amarasinghe GK. Ebolavirus VP35 is a multifunctional virulence factor. Virulence. 2010 Nov-Dec; 1(6):526-31.
      View in: PubMed
    31. Fytas C, Kolocouris A, Fytas G, Zoidis G, Valmas C, Basler CF. Influence of an additional amino group on the potency of aminoadamantanes against influenza virus A. II - Synthesis of spiropiperazines and in vitro activity against influenza A H3N2 virus. Bioorg Chem. 2010 Dec; 38(6):247-51.
      View in: PubMed
    32. Prins KC, Binning JM, Shabman RS, Leung DW, Amarasinghe GK, Basler CF. Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J Virol. 2010 Oct; 84(20):10581-91.
      View in: PubMed
    33. Medina RA, Manicassamy B, Stertz S, Seibert CW, Hai R, Belshe RB, Frey SE, Basler CF, Palese P, García-Sastre A. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun. 2010; 1:28.
      View in: PubMed
    34. Leung DW, Borek D, Farahbakhsh M, Ramanan P, Nix JC, Wang T, Prins KC, Otwinowski Z, Honzatko RB, Helgeson LA, Basler CF, Amarasinghe GK. Crystallization and preliminary X-ray analysis of Ebola VP35 interferon inhibitory domain mutant proteins. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 Jun 1; 66(Pt 6):689-92.
      View in: PubMed
    35. Leung DW, Shabman RS, Farahbakhsh M, Prins KC, Borek DM, Wang T, Mühlberger E, Basler CF, Amarasinghe GK. Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J Mol Biol. 2010 Jun 11; 399(3):347-57.
      View in: PubMed
    36. Manicassamy B, Medina RA, Hai R, Tsibane T, Stertz S, Nistal-Villán E, Palese P, Basler CF, García-Sastre A. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog. 2010 Jan; 6(1):e1000745.
      View in: PubMed
    37. Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF, Amarasinghe GK. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol. 2010 Feb; 17(2):165-72.
      View in: PubMed
    38. Valmas C, Grosch MN, Schümann M, Olejnik J, Martinez O, Best SM, Krähling V, Basler CF, Mühlberger E. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 2010 Jan; 6(1):e1000721.
      View in: PubMed
    39. Prins KC, Delpeut S, Leung DW, Reynard O, Volchkova VA, Reid SP, Ramanan P, Cárdenas WB, Amarasinghe GK, Volchkov VE, Basler CF. Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol. 2010 Mar; 84(6):3004-15.
      View in: PubMed
    40. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, Hai R, Basler CF, Crowe JE. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol. 2010 Mar; 84(6):3127-30.
      View in: PubMed
    41. Xu R, McBride R, Paulson JC, Basler CF, Wilson IA. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol. 2010 Feb; 84(4):1715-21.
      View in: PubMed
    42. Martínez-Sobrido L, Cadagan R, Steel J, Basler CF, Palese P, Moran TM, García-Sastre A. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol. 2010 Feb; 84(4):2157-63.
      View in: PubMed
    43. Mateo M, Reid SP, Leung LW, Basler CF, Volchkov VE. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol. 2010 Jan; 84(2):1169-75.
      View in: PubMed
    44. Martinez O, Johnson J, Manicassamy B, Rong L, Olinger GG, Hensley LE, Basler CF. Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol. 2010 Feb; 12(2):148-57.
      View in: PubMed
    45. Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res. 2009 Sep; 29(9):511-20.
      View in: PubMed
    46. Ciancanelli MJ, Volchkova VA, Shaw ML, Volchkov VE, Basler CF. Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol. 2009 Aug; 83(16):7828-41.
      View in: PubMed
    47. Kulkarni S, Volchkova V, Basler CF, Palese P, Volchkov VE, Shaw ML. Nipah virus edits its P gene at high frequency to express the V and W proteins. J Virol. 2009 Apr; 83(8):3982-7.
      View in: PubMed
    48. Leung DW, Ginder ND, Nix JC, Basler CF, Honzatko RB, Amarasinghe GK. Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Feb 1; 65(Pt 2):163-5.
      View in: PubMed
    49. Prins KC, Cárdenas WB, Basler CF. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol. 2009 Apr; 83(7):3069-77.
      View in: PubMed
    50. Leung DW, Ginder ND, Fulton DB, Nix J, Basler CF, Honzatko RB, Amarasinghe GK. Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):411-6.
      View in: PubMed
    51. Martinez O, Tsibane T, Basler CF. Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol. 2009; 28(1):69-92.
      View in: PubMed
    52. Aiki-Raji CO, Aguilar PV, Kwon YK, Goetz S, Suarez DL, Jethra AI, Nash O, Adeyefa CA, Adu FD, Swayne D, Basler CF. Phylogenetics and pathogenesis of early avian influenza viruses (H5N1), Nigeria. Emerg Infect Dis. 2008 Nov; 14(11):1753-5.
      View in: PubMed
    53. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008 Sep 25; 455(7212):532-6.
      View in: PubMed
    54. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cárdenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting AT. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 2008 Sep; 9(9):930-6.
      View in: PubMed
    55. Basler CF, Aguilar PV. Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res. 2008 Sep; 79(3):166-78.
      View in: PubMed
    56. Aguilar PV, Leung LW, Wang E, Weaver SC, Basler CF. A five-amino-acid deletion of the eastern equine encephalitis virus capsid protein attenuates replication in mammalian systems but not in mosquito cells. J Virol. 2008 Jul; 82(14):6972-83.
      View in: PubMed
    57. Pappas C, Aguilar PV, Basler CF, Solórzano A, Zeng H, Perrone LA, Palese P, García-Sastre A, Katz JM, Tumpey TM. Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3064-9.
      View in: PubMed
    58. Basler CF. Influenza viruses: basic biology and potential drug targets. Infect Disord Drug Targets. 2007 Dec; 7(4):282-93.
      View in: PubMed
    59. Reid SP, Valmas C, Martinez O, Sanchez FM, Basler CF. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol. 2007 Dec; 81(24):13469-77.
      View in: PubMed
    60. Martinez O, Valmas C, Basler CF. Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology. 2007 Aug 1; 364(2):342-54.
      View in: PubMed
    61. Aguilar PV, Weaver SC, Basler CF. Capsid protein of eastern equine encephalitis virus inhibits host cell gene expression. J Virol. 2007 Apr; 81(8):3866-76.
      View in: PubMed
    62. Basler CF, García-Sastre A. Sensing RNA virus infections. Nat Chem Biol. 2007 Jan; 3(1):20-1.
      View in: PubMed
    63. Ciancanelli MJ, Basler CF. Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol. 2006 Dec; 80(24):12070-8.
      View in: PubMed
    64. Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, Basler CF, Palese P, Taubenberger JK, García-Sastre A, Swayne DE, Katze MG. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature. 2006 Oct 5; 443(7111):578-81.
      View in: PubMed
    65. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol. 2006 Jun; 80(11):5156-67.
      View in: PubMed
    66. Cárdenas WB, Loo YM, Gale M, Hartman AL, Kimberlin CR, Martínez-Sobrido L, Saphire EO, Basler CF. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol. 2006 Jun; 80(11):5168-78.
      View in: PubMed
    67. Tumpey TM, García-Sastre A, Taubenberger JK, Palese P, Swayne DE, Pantin-Jackwood MJ, Schultz-Cherry S, Solórzano A, Van Rooijen N, Katz JM, Basler CF. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol. 2005 Dec; 79(23):14933-44.
      View in: PubMed
    68. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solórzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, García-Sastre A. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005 Oct 7; 310(5745):77-80.
      View in: PubMed
    69. Glaser L, Stevens J, Zamarin D, Wilson IA, García-Sastre A, Tumpey TM, Basler CF, Taubenberger JK, Palese P. A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol. 2005 Sep; 79(17):11533-6.
      View in: PubMed
    70. Reid SP, Cárdenas WB, Basler CF. Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology. 2005 Oct 25; 341(2):179-89.
      View in: PubMed
    71. Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF. Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol. 2005 May; 79(10):6078-88.
      View in: PubMed
    72. Basler CF, García-Sastre A, Palese P. A novel paramyxovirus? Emerg Infect Dis. 2005 Jan; 11(1):108-12.
      View in: PubMed
    73. Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant. 2004 Nov; 4(11):1805-9.
      View in: PubMed
    74. Donelan NR, Dauber B, Wang X, Basler CF, Wolff T, García-Sastre A. The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol. 2004 Nov; 78(21):11574-82.
      View in: PubMed
    75. Kash JC, Basler CF, García-Sastre A, Carter V, Billharz R, Swayne DE, Przygodzki RM, Taubenberger JK, Katze MG, Tumpey TM. Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J Virol. 2004 Sep; 78(17):9499-511.
      View in: PubMed
    76. Shaw ML, García-Sastre A, Palese P, Basler CF. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol. 2004 Jun; 78(11):5633-41.
      View in: PubMed
    77. Tumpey TM, García-Sastre A, Taubenberger JK, Palese P, Swayne DE, Basler CF. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A. 2004 Mar 2; 101(9):3166-71.
      View in: PubMed
    78. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science. 2004 Mar 19; 303(5665):1866-70.
      View in: PubMed
    79. Donelan NR, Basler CF, García-Sastre A. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol. 2003 Dec; 77(24):13257-66.
      View in: PubMed
    80. Park MS, García-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol. 2003 Sep; 77(17):9522-32.
      View in: PubMed
    81. Flandorfer A, García-Sastre A, Basler CF, Palese P. Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin. J Virol. 2003 Sep; 77(17):9116-23.
      View in: PubMed
    82. Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Mühlberger E, Bray M, Klenk HD, Palese P, García-Sastre A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol. 2003 Jul; 77(14):7945-56.
      View in: PubMed
    83. Park MS, Shaw ML, Muñoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, García-Sastre A, Basler CF. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol. 2003 Jan; 77(2):1501-11.
      View in: PubMed
    84. Wang X, Basler CF, Williams BR, Silverman RH, Palese P, García-Sastre A. Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol. 2002 Dec; 76(24):12951-62.
      View in: PubMed
    85. Tumpey TM, García-Sastre A, Mikulasova A, Taubenberger JK, Swayne DE, Palese P, Basler CF. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A. 2002 Oct 15; 99(21):13849-54.
      View in: PubMed
    86. Palese P, Basler CF, García-Sastre A. The makings of a killer. Nat Med. 2002 Sep; 8(9):927-8.
      View in: PubMed
    87. Geiss GK, Salvatore M, Tumpey TM, Carter VS, Wang X, Basler CF, Taubenberger JK, Bumgarner RE, Palese P, Katze MG, García-Sastre A. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16):10736-41.
      View in: PubMed
    88. Basler CF, García-Sastre A. Viruses and the type I interferon antiviral system: induction and evasion. Int Rev Immunol. 2002 Jul-Oct; 21(4-5):305-37.
      View in: PubMed
    89. Salvatore M, Basler CF, Parisien JP, Horvath CM, Bourmakina S, Zheng H, Muster T, Palese P, García-Sastre A. Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol. 2002 Feb; 76(3):1206-12.
      View in: PubMed
    90. Basler CF, Reid AH, Dybing JK, Janczewski TA, Fanning TG, Zheng H, Salvatore M, Perdue ML, Swayne DE, García-Sastre A, Palese P, Taubenberger JK. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2746-51.
      View in: PubMed
    91. Momose F, Basler CF, O'Neill RE, Iwamatsu A, Palese P, Nagata K. Cellular splicing factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the influenza virus nucleoprotein and enhances viral RNA synthesis. J Virol. 2001 Feb; 75(4):1899-908.
      View in: PubMed
    92. Basler CF, Wang X, Mühlberger E, Volchkov V, Paragas J, Klenk HD, García-Sastre A, Palese P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):12289-94.
      View in: PubMed
    93. Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P, García-Sastre A. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol. 2000 Sep; 74(17):7989-96.
      View in: PubMed
    94. Basler CF, García-Sastre A, Palese P. Mutation of neuraminidase cysteine residues yields temperature-sensitive influenza viruses. J Virol. 1999 Oct; 73(10):8095-103.
      View in: PubMed
    95. Basler CF, Droguett G, Horwitz MS. Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35. Gene. 1996 May 8; 170(2):249-54.
      View in: PubMed
    96. Basler CF, Horwitz MS. Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. Virology. 1996 Jan 15; 215(2):165-77.
      View in: PubMed
    Basler's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067